KAFOCIN Drug Patent Profile
✉ Email this page to a colleague
When do Kafocin patents expire, and what generic alternatives are available?
Kafocin is a drug marketed by Lilly and is included in one NDA.
The generic ingredient in KAFOCIN is cephaloglycin. Additional details are available on the cephaloglycin profile page.
Summary for KAFOCIN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 32 |
Patent Applications: | 3,144 |
Formulation / Manufacturing: | see details |
DailyMed Link: | KAFOCIN at DailyMed |
US Patents and Regulatory Information for KAFOCIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lilly | KAFOCIN | cephaloglycin | CAPSULE;ORAL | 050219-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |